Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How exactly do DOCTORS confirm if a drug was solely responsible for saving a life?---
And there is no question in anyone who watched my son what saved his life It was leronlimab !!!!
Please give the name of the test or data which confirms it.
Actually, we both know it really doesnt matter...your stock is at 14 cents trending to zero anyways.
Alright janice, I'll give you a golf clap for bringing the Borgers info to the board.
Ive been bringing info to this board for years and been 90%+ correct about my predictions/observations so dont let one tidbit of info go to ones head.
DON'T EVEN TRY TO PUT LIPSTICK ON THIS PIG--- Oh that idiot will try it, watch and see.
Arguing a 14 cent stock with current SEC and DOJ investigations, public FDA rebuke, revolving door top execs, resigned execs, arrested and indicted exec, lawsuits, no money, revolving door accountants, no approvals anywhere in the entire world, recent new low in da 12 cents range, etc etc etc will definitely try to put lipstick on this pig....all for naught.
INSANITY
Think about this- The SEC selectively banned Borgers less than 1 month before CYDYs fiscal year ends.
Marinade on that.
Yes janice, a problem indeed...either a late 10K or no 10K whatsoever---
On October 6, 2023, the Audit Committee engaged BF Borgers CPA PC (“BF Borgers”) and appointed the firm as the Company’s independent registered public accounting firm for the Company’s fiscal year ended May 31, 2024.
https://www.sec.gov/Archives/edgar/data/1175680/000155837023016328/cydy-20231006x8k.htm
Starting to add up why CYDY would choose a "Delinquent" status auditor in the first place.
The SEC had this to say--- "Borgers and his sham audit mill have been permanently shut down.”
https://www.sec.gov/news/press-release/2024-51
Yep, lets see how CYDY spins it.
CYDY asked for Borgers and got it. Borgers went for the longest time as "Delinquent" status in their state...they were delinquent when CYDY signed them on.
Sounds kinda expensive for CYDY to possibly find another accountant and/or restate some financials.
Good info janice! Lets see what CYDYs response will or will not be on an 8K next week.
Dropped to da 12s today. TRUTH or "bashing"?
Dupes look more ridiculous than ever.
Waaaaah CYDY closed in da 13s somebody tell me where I can file a complaint!
Booo hoo hoo waaaah Im hurt!
LAUGHING
Nadar got charged with insider trading while Scott didn't---All the more reason for NP to scream "how the hell did I get charged and they didnt".
Eventually we will see how this all plays out.
CYDY in da 13s today...share price going from bad to worse.
Not a good look for the "con man".
WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE!!!!!!!
sloppy attempt ???--Sounds like the ramblings of a terrified and nervous bagholder.
Every word quoted is directly from the Wall Street Journal.
As the stock trends closer and closer to zero, new bagholder aliases are getting flushed out into the open left and right.
What about Brucie pumping Operation Warp Speed?---
Small Biotech Stock CytoDyn Soars on ‘Warp Speed’ Comment
By Michael Wursthorn
Updated Aug. 26, 2020 9:18 pm ET
The market for small biotechs working on coronavirus treatments is so hot that sometimes all it takes is a whisper to send a stock soaring.
So it was with CytoDyn Inc. , which climbed more than 20% after a former adviser told television host Dr. Drew Pinksy on Thursday that he thought the company would move forward with a federal-government program aimed at fast- tracking virus treatments.
CytoDyn isn't being considered for the program, known as Operation Warp Speed, according to a senior administration official.
Yet in the quick-punch world of retail investing, the video clip of the former adviser, Bruce Patterson , has already gone viral. Investors who closely follow the company shared it on social media and message boards, including Investors Hub, a forum popular with penny-stock traders. Shares of CytoDyn rallied 13% to $3.43 a share on Friday, notching the company's biggest daily gain in about a month, before rising another 12% on Monday.
CytoDyn Shares have plateaued since then, declining a more than 2% over the last two trading sessions.
Operation Warp Speed is a federal initiative to accelerate the development and manufacturing of drugs and vaccines for Covid-19, which has claimed more than 175,000 lives in the U.S. Through the program, the government has given funding to companies such as Moderna Inc. , Novavax Inc. and Regeneron Pharmaceuticals Inc.
The senior administration official said CytoDyn had only completed a preliminary qualification for being included in the initiative. The Vancouver, Wash ., company had submitted information through a so-called CoronaWatch, a program run by the Biomedical Advanced Research and Development Authority , or Barda, to assess the viability of drugs and therapeutics that might be effective against Covid-19, the official said. Technical experts reviewed the submission and opted not to proceed further at this time, the official added.
The team responsible for reviewing the materials makes clear to companies that submissions are for informational purposes only and don't lead to funding on their own, the official added. Companies must apply to specific grant programs to receive funding, the official said, which CytoDyn hasn't done at this time.
Dr. Patterson told The Wall Street Journal that he helped arrange an initial exchange of information between CytoDyn and Barda. He hadn't been involved in further discussions, he said.
CytoDyn declined to comment on the exchange or on any communication with Operation Warp Speed.
" CytoDyn received an email. I received an email from Operation Warp Speed. So yes they are aware of it," Dr. Patterson said in the video. "And I think we'll move forward with them."
The company hired Dr. Patterson as an adviser, in addition to hiring his company, IncellDx, to provide diagnostic services. CytoDyn and Dr. Patterson said his tenure as a consultant ended in May. CytoDyn also no longer uses Dr. Patterson's company for diagnostic services.
An April securities filing disclosed that Dr. Patterson was a CytoDyn shareholder.
In the interview with the Journal, Dr. Patterson said he never received paperwork regarding his ownership in CytoDyn . "I've gotten little to no paperwork regarding that," he said. "I don't think of it as real."
On the question of Dr. Patterson's share ownership, Arian Colachis , CytoDyn's general counsel, pointed to the April filing.
"The document speaks for itself, and we have no further comment," she said.
Write to Michael Wursthorn at Michael.Wursthorn@wsj.com
(END) Dow Jones Newswires
08-26-20 1145ET
Copyright (c) 2020 Dow Jones & Company, Inc.
CYDY back in da 14s today. BWWWAAAAAAHAHAHAHA!!!
Dupes touting leronsaline is safe as a tic tac. Who is dumb enough to believe a tic tac would cure HIV or covid then whine about the share price downfall is all the "bashers" fault?
LAUGHING
Did CYDY in their own words tell the SEC they would remove language that states or implies that it believes leronsaline is safe and effective or that leronsaline is likely to be found safe and effective or not?
Yes or no? https://www.sec.gov/Archives/edgar/data/1175680/000119312521171425/filename1.htm
Truth or "bashing"?
Is ((((((((LERONSALINE)))))))) safe and effective? NOPE!---
1. We note statements in your proposed disclosure for Item 1 and Note 4 that you believe leronlimab is safe and effective, as well as language implying the existence of “clinical data that supports its safety and efficacy.” As safety and efficacy determinations are within the authority of the U.S. Food and Drug Administration and comparable regulatory bodies, please revise your proposed disclosure to remove language that states or implies that you believe leronlimab is safe and effective or that leronlimab is likely to be found safe and effective.
RESPONSE:
The Company will revise its proposed disclosure to remove language that states or implies that it believes leronlimab is safe and effective or that leronlimab is likely to be found safe and effective.
https://www.sec.gov/Archives/edgar/data/1175680/000119312521171425/filename1.htm
Yes this mother is in medical profession-- More fucking lies from you.
A mother IN the medical profession is either currently licensed or employed via proof of paying taxes on income of said medical profession. You are neither.
A retired doctor is just that. Lets see a retired unlicensed doctor perform a surgery in a clinic or hospital. That being said, he or she is no longer a doctor.
A washed up liar losing money on a OTC penny stock is a more fitting definition of a pumping individual whom is NOT in the medical profession.
Truth??? These are both LIES--- 1. "a mother in the medical field" (which is patently false, the mother WAS NOT licensed in the medical field at the time of this article).
2. "CytoDyn, appears to be the only biotech company with a proven treatment in a large randomized controlled trial for severe and critical COVID-19." which is ANOTHER blatant lie.
Which online financial publication had the story of leronlimab damaged their twins posted?
Was it posted on Zerohedge?
Zerohedge says--- the zero hedge manifesto
our mission:
to widen the scope of financial, economic and political information available to the professional investing public.
https://www.zerohedge.com/about
Dont even get me started on the never purchased CYDY warrants at a discounted price lies.
and all of them showing us work of FDA.--- Point taken. So what is it called when "a mother in the medical field" (which is patently false, the mother WAS NOT licensed in the medical field at the time of this article) refuses to divulge her active and current investment in the drug and company touted in this article and then to add insult to injury claims "CytoDyn, appears to be the only biotech company with a proven treatment in a large randomized controlled trial for severe and critical COVID-19." which is ANOTHER patently untrue lie?
Leronlimab Anecdotes - A Patient's Perspective - Beating the System
BY CHESSMASTER
THURSDAY, AUG 12, 2021 - 22:03
CytoDyn, appears to be the only biotech company with a proven treatment in a large randomized controlled trial for severe and critical COVID-19. Proven means their drug reduced 14 day mortality by 82% in a phase 3 clinical trial. Proven doesn't mean the drug is approved by the FDA because they asked for more data. This is the rub because it's proven, but not approved and because of that the company has been under constant assault and criticism for how the management team has been handling the clinical trials. Their leading drug candidate is called leronlimab and is branded as Vyrologix and it has single handedly taken dying from COVID-19 off the table. Many of the critics of the Company are shareholders and in one special case a group of shareholders that called themselves Advancing Leronlimab and used what the Company described and illegal tactics to challenge the board of directors. Luckily for patients around the world their bid for greed and avarice failed.
When you put aside the greed and take a hard look at the company, their mission statement is to save lives and of course maximize shareholder value. This management team may be tiny in comparison to most biotechs, but enormous in terms of heart. This team actually cares for patients personally and at one time in the pandemic had the largest number of compassionate use approvals. The truth is that there’s only one reason for breaking a record for compassionate use and it has to do with the viability of the treatment. Many that have gotten either compassionate use or the rarely used Right to Try approvals have interfaced with top management as they worked tirelessly to get the approvals processed as quickly as possible.
Shareholders that have a hard time understanding how a drug with so much potential isn't approved by now don't understand how challenging the drug development process is, and they certainly don’t understand a management that seems to put patients’ lives first. At CytoDyn the CEO has gotten himself personally involved in pushing the process of many Emergency IND’s and compassionate use requests. This is not a normal thing that people are likely to see at any other biotech on the globe. The corporate culture really values human life and seems to do anything they can to preserve it.
Leronlimab has saved many lives. A very recent anecdotal report of another life saved by leronlimab underscores the importance of how truly revolutionary this drug could become. In order to preserve the privacy of the patient no identifying details will be used. Approximately 2 weeks ago a mother in the medical field was talking to her grown son who is also in the medical field and noticed over the phone that he sounded sick and nasally. The son indicated that he just had a bad cold and that something was going around because he thought since all people were all wearing masks for so long that their natural immunity was compromised and colds were on the rise. The mom was skeptical of the answer and made him take a home covid test from the pharmacy. Although he tested positive, the mom was well versed in treatment options and was prepared. She pumped him up with ivermectin, vitamins and eventually resorted to hydroxychloroquine. Nothing seemed to work, and after a couple of days his oxygen levels eventually dropped into the mid 70’s forcing him to call an ambulance. When he arrived he found himself in an unfortunate situation. The Floridian healthcare system was experiencing a surge and was overrun with patients. After many hours of waiting he was diagnosed via a chest X ray having double lobe pneumonia, no treatment was administered and the son found his way back home after picking up a canister of oxygen to use at home. During his wait in the Emergency room he was not provided water, or intravenous fluids, or a bed to lay down on. Despite his use of oxygen at home his oxygen levels continued to deteriorate to 74%. He could barely breathe or talk. This put him at severe risk of dying, he needed to get back to the hospital. The surrounding hospitals were all full capacity so the resourceful mom called around looking for open beds. Eventually he was admitted to another hospital with a compassionate doctor leading the treatment. The first treatment offered was Remdesivir and that was patently rejected by the mom who read the reports and understood it was not appropriate for her son's situation. This was a cytokine storm not a viral infection. She made it known that she wanted leronlimab to be used for her son. Instead of saying no, the doctor suggested they try one of the approved options like tocilizumab first and see if there was any change before they go the Right to Try route. After 3 days of seeing continued deterioration the Right to Try paperwork was signed by the doctor. The drug made it to the hospital the very next day. This was very A-typical because the mom was completely prepared and was on top of the communication.
Before taking leronlimab the patient was on high flow oxygen consuming between 6 – 10 liters. Since leronlimab is a subcutaneous shot it takes time to enter the bloodstream and she cautioned her son to remain patient. After administration it took two hours before there was a change in his status. The patient was able to talk better and had a more productive cough and the oxygen saturation levels started to increase. After 4-5 hours oxygen levels improves so much high flow oxygen was removed and reduced to the nasal cannula. The patient's strength was coming back and he felt like leaving the hospital, but there was also pressure for him to leave to make room for the sick that were in the hallways. The patient was ultimately discharged 26 hours after being injected with leronlimab, and went home with instructions to use oxygen as needed and report back if there was a worsening of conditions.
All these anecdotal patients that took leronlimab, which numbers over 100 understand one truth. The drug works and works extremely well and in most cases quickly. The last thing these patients care about is the greed involved in developing a drug and the he said she said minutia in the boardroom. They welcome a CEO and a company with a refreshing attitude that just wants to save lives. Critically ill patients have been abandoned by both the FDA with their draconian policies and politicians whom seem to be more concerned about mandating vaccines and masks. Team CytoDyn and Hero moms need to be celebrated whenever possible.
The measures to curb the pandemic failed with over 620,000 American in body bags. Initial estimates were 200,000. History will eventually reflect upon how many lives that could have been saved if leronlimab was approved sooner. There is still a long approval road ahead for leronlimab in the United States, but Brazil has their own pivotal trial starting imminently and may be the first beneficiary of a COVID drug that takes dying off the table and flattens the curve.
The situation in Florida with respect to available ICU beds is really bad and here sits a drug that saves the lives of almost everyone it touches. It also has the potential to seriously flatten the curve in hard hit areas because if all the people sitting in the hallways were given this very safe drug they might actually go home like this patient did. People need to know about this drug and the process required to get it. Right now it's only available via Right to Try since it doesn't have its EUA approval or any active clinical trial sites in the USA. Eventually the FDA will come around to approving this drug but in the meantime it's pointless to provoke the FDA and try to force an approval. That's been tried before and has failed. People just need to work within the system to get the drug for your loved ones should they need it. The hero mom in this story was well educated and prepared on what to do in case of this eventuality. Advanced preparedness seems to be partly responsible for the happy ending. So the lesson learned here is that there is no substitute for preparation. It's clear that this drug takes dying off the table and when politicians decide they've seen enough body bags then maybe this drug will see the light of day for use in COVID-19 in the United States.
Right to Try is the only way to access leronlimab and take dying off the table for severe to critical patients. The only hitch is that you have to ask for it and you have to get a doctor at the hospital willing to step up. These anecdotal reports are just whispers right now, but they will turn into a thunderous call to action as the pandemic worsens and news of the drugs success continues to spread.
Enough with the fantasy lies--- Leronlimab was proven being effective many times
We've been over this time and time and time again and it always boils down to me asking the same question and me getting the same non-answer...link the goddam data from an OFFICIAL source (FDA, NIH, etc) proving---
—-Phase 3 pivotal study for combo HIV , finished with 81% efficacy , and not one serious side effect. When at the time 2 other approved drugs were ,maraviroc with 45% , and Ibalizumab with 43%
—- CD12 study in critical Covid showed ,
82% mortality benefit ABOVE any drug in the world , when leronlimab was in the system ..
—-small study in cancers showed really positive results …
—-as also in Nash …
-—Long Covid study was a big success , it showed that some patients immune system is hyperactive , but many are immunosuppressed , leronlimab worked as a great immunemodulator in both ..
This study was peer reviewed and published by Dr Otto Yang from UCLA..
Bad FDA tactics? Has leronsaline met its primary endpoints in any of its numerous clinical trials?
So cut the email and conspiracy shit...has leronsaline been proven to be effective or not?
Now one can see why investors admit to being hurt.
Is stating nobody interested in 15 cent shares "bashing" or a fact?
LAUGHING at hurt dupes.
PROVE IT with links or screen shots--- Do what my investigations did- call FDA. Answer is yes and confirmed.
RE: Dr. Lalezari (current CYDY CEO) served as Principal Investigator on clinical trials conducted for Merck, Bayer, Pfizer, and Roche,
The "lame bashing technique" is based on and confirmed with links by verifiable SEC filings, PRs, and conference call yip yap.
Ohhh, looky, it climbed to 15 cents today.
LAUGHING at hurt dupes.
And what does this Cytodyn PR say?--- Dr. Lalezari served as Principal Investigator on clinical trials conducted for Merck, Bayer, Pfizer, and Roche, to name a few.
https://www.biospace.com/article/releases/cytodyn-selects-b-quest-clinical-research-b-for-next-trial-of-hiv-aids-immune-therapy-/
Is the above quote true or false?
Pretty sure I asked you about this but you never gave a response.
Point out on the clinical trial.gov website where the current CEO (Lalezari) served as Principal Investigator on clinical trials conducted for Merck, Bayer, Pfizer, and Roche.
Please, no idiotic mumbo jumbo which you 14 cent per share dupes are famous for, just answer the fucking question.
100% absolute PROOF of how stupid these longs are--- So was the Hold Lifted in the 10K or does it need to be 8K’d?
Heres what the 10K says dumdum:
In particular, there is no guarantee that the FDA will lift the partial clinical hold placed on our HIV program.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1175680/000155837023015718/cydy-20230531x10k.htm
Hits da ((((((((12s))))))))!!! Bashers! Manipulation! Waaaaaah!
LAUGHING
Um, mr (see my profile pic), bankruptcy statements based on--- Since our inception, we have been insolvent and have required debt and equity financing to maintain operations. We expect our debt service obligations and our need for additional funding to finance operations will cause additional substantial dilution to our existing stockholders and could adversely affect the trading price of our common stock.
https://www.sec.gov/Archives/edgar/data/1175680/000155837023015718/cydy-20230531x10k.htm
Winding down statement based on--- On April 3, 2024, CytoDyn Inc. (the “Company”) and Samsung BioLogics Co., Ltd. (“Samsung”) executed an agreement (the “Letter Agreement”), wherein the parties reached agreement for an orderly process for winding down services and a restructuring of the amount payable by the Company to Samsung (the “Total Balance”). The Letter Agreement resolves the Company’s obligations under the Master Services Agreement and related ancillary agreements first entered into between Samsung and the Company in or around April 2019 (collectively, the “Agreement”).
https://www.sec.gov/Archives/edgar/data/1175680/000155837024004802/cydy-20240403x8k.htm
The above is definitely a provision for payment of the debts and other liabilities of the Company---
3. Liquidation. Upon the dissolution, liquidation or winding up of the Company, after payment or provision for payment of the debts and other liabilities of the Company and subject to the rights, if any, of the holders of any outstanding series of Preferred Stock or any class or series of stock having a preference over or the right to participate with the Common Stock with respect to the distribution of assets of the Company upon such dissolution, liquidation or winding up of the Company, the holders of Common Stock shall be entitled to receive the remaining assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held by them.
https://www.sec.gov/Archives/edgar/data/1175680/000155837024000836/cydy-20240130xex3d1.htm
All *their* words, not mine or anyone elses.
GIVING FINANCIAL ADVICE--- Thats just *your* ignorant interpretation....in reality its the SEC filings, PRs, conference calls, etc, that are giving the financial advice...parroting exactly what the published filings, PRs, and etc say is not giving financial advice.
You *confirmed* dumbass losers need to find another scapegoat for your ignorant investment decisions.
So name the LIES dumdum...wait, you cant or you already wouldve.
LAUGHING
Um, mr (see my profile pic), stop lying. The key ingredient to "manipulation" is dissemination of misinformation (lying).
Since all the "bashing" on this message board is derived directly from SEC filings, PRs, conference calls, etc, point out exactly which lies have manipulated this stock to 15 cents.
WAITING
CYDY closed the week in da 15s and the best these dumbass losers and the c-jock can come up with is hillbilly and pigeons.
PATHETIC
The market is trying to tell you fools something. The market is dumping.
Yes kgro, anything to distract the FACT that Mitch has started the winding up process.
Lets see pumpers post the DOJ emails to CYDY regarding Securities and Exchange Commission and Department of Justice Investigations---
The Company has received subpoenas from the SEC and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain former Company executives and directors have received subpoenas concerning similar issues and have been interviewed by the DOJ and SEC, including the Company’s former CEO, Nader Z. Pourhassan.
https://www.sec.gov/Archives/edgar/data/1175680/000155837024000305/cydy-20231130x10q.htm
Emails this, emails that...has leronsaline been proven to be effective? NOPE!!!
Closed in da 15s...cmon losers, tell me what a great stock this is and how "bashers" were/are always wrong about this garbage.
BWWAAAAHAHAHAHAHA
Roger that TDK. Not only that but this quote in particular reads like a last will and testament--- and will be transitioning the aforementioned services to one, or several, of its CURRENT SERVICE PROVIDERS
Yup. Looks like Mitch is shifting the plan into gear...its over.
Um fish, nothing "boilerplate" about it...Mitch is doing exactly what folks here initially rumored him to do.
Its happening..."winding down" now all of a sudden a reality with Samsung being the first shoe to drop.
3. Liquidation. Upon the dissolution, liquidation or winding up of the Company, after payment or provision for payment of the debts and other liabilities of the Company and subject to the rights, if any, of the holders of any outstanding series of Preferred Stock or any class or series of stock having a preference over or the right to participate with the Common Stock with respect to the distribution of assets of the Company upon such dissolution, liquidation or winding up of the Company, the holders of Common Stock shall be entitled to receive the remaining assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held by them.
https://www.sec.gov/edgar/search/?r=el#/q=winding&page=1&ciks=0001175680&entityName=CytoDyn%2520Inc.%2520%2520(CIK%25200001175680)&category=form-cat0&forms=-3%252C%2520-4%252C%2520-5&sort=desc
Looks like the winding up of the affairs of the Company has begun---
the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the affairs of the Company; and
https://www.sec.gov/Archives/edgar/data/1175680/000155837024000836/cydy-20240130xs1.htm
Welch owns close to 50 MILLION shares of CYDY. The filing says--
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
https://www.sec.gov/Archives/edgar/data/1175680/000119312524032312/d778219dsc13ga.htm
Speaking of results, where exactly can the 82% nonsense youve been yodeling for years be found on the clinical trials.gov website?
Please point that out with link included.
I found the Principal Investigator list so why didnt CYDY want to divulge a designated PI on the main Study page?---
Contacts/Locations
Central Contact Person
Name
Kush Dhody, MBBS, MS, CCRA
Telephone
301-956-2536
Email
kushd@amarexcro.com
Study Officials
Location
Alexander City, Alabama, United States, 35010
Status:
Recruiting
Facility:
Advanced Cardiovascular, LLC
Contact:
Contact
Sabrina Forbus, RN, BSN
256-215-5323
Principal Investigator
William Ross Davis, MD
Fullerton, California, United States, 92835
Status:
Recruiting
Facility:
St. Jude Medical Center
Contact:
Contact
Blanca Sanchez
714-446-5620
Blanca.Sanchez@stjoe.org
Principal Investigator
David J Park, MD
Los Angeles, California, United States, 90095
Status:
Recruiting
Facility:
UCLA
Contact:
Contact
Nancy Lopez
310-794-8043
NancyRLopez@mednet.ucla.edu
Principal Investigator
Otto Yang, MD
Tampa, Florida, United States, 33612
Status:
Recruiting
Facility:
James A. Haley Veterans' Hospital
Contact:
Contact
Adam Zoble
813-631-3671
Adam.Zoble@va.gov
Principal Investigator
Koushik Reddy, MD
Gainesville, Georgia, United States, 30501
Status:
Active, not recruiting
Facility:
Center for Advanced Research & Education (CARE)
Boston, Massachusetts, United States, 02215
Status:
Recruiting
Facility:
Beth Israel Deaconess Medical Center
Contact:
Contact
Caitlin Davis
617-735-4466
Cdavis6@bidmc.harvard.edu
Principal Investigator
Sabrina Tan, MD
Livingston, New Jersey, United States, 07052
Status:
Recruiting
Facility:
St. Barnabas
Contact:
Principal Investigator
Subroto Paul, MD
Morristown, New Jersey, United States, 07962-1905
Status:
Recruiting
Facility:
Atlantic Health System Hospital
Contact:
Principal Investigator
Eric Whitman, MD
Teaneck, New Jersey, United States, 07666
Status:
Recruiting
Facility:
Holy Name Medical Center
Contact:
Contact
Patty Kiledjian
201-541-6312
pkiledjian@holyname.org
Principal Investigator
Benjamin De La Rosa, MD
Bronx, New York, United States, 10467
Status:
Recruiting
Facility:
Montefiore Medical Center
Contact:
Contact
Jane Wilson
718-920-7916
Principal Investigator
Harish Seethamraju, MD
Brooklyn, New York, United States, 11229
Status:
Recruiting
Facility:
New York Community Hospital of Brooklyn
Contact:
Contact
Marina Bilik
718-692-5336
mbilik@nych.com
Principal Investigator
Isaia Avraham, MD
Winston-Salem, North Carolina, United States, 27103
Status:
Recruiting
Facility:
Novant Health
Contact:
Contact
Shannon Bowman
shannon.bowman@novanthealth.org
Contact
Pailing Richards
704-996-7627
pcrichards@novanthealth.org
Principal Investigator
Michael Morgan, MD
Columbus, Ohio, United States, 43215
Status:
Recruiting
Facility:
Ohio Health
Contact:
Principal Investigator
Kiran Devulapally, MD
Corvallis, Oregon, United States, 97330
Status:
Recruiting
Facility:
Good Samaritan Hospital Corvallis
Contact:
Contact
Stephanie Mock
541-768-4352
stmock@samhealth.org
Principal Investigator
Brian Delmonaco, MD
Portland, Oregon, United States, 97239
Status:
Recruiting
Facility:
Oregon Health and Sciences University
Contact:
Principal Investigator
Marcel Curlin, MD
Dallas, Texas, United States, 75204
Status:
Recruiting
Facility:
Baylor Scott & White Research Institute
Contact:
Contact
Samantha Wang
Samantha.wang@bswhealth.org
Principal Investigator
Uriel Sandkovsky
Houston, Texas, United States, 77030
Status:
Recruiting
Facility:
Baylor College of Medicine
Contact:
Contact
Hinali Zaveri, MD
713-873-2353
hzaveri@bcm.edu
Principal Investigator
Kalpalatha Guntupalli, MD
Houston, Texas, United States, 77030
Status:
Recruiting
Facility:
University of Texas
Contact:
Contact
Jordan Lake
713-500-6767
Jordan.e.lake@uth.tmc.edu
Principal Investigator
Jordan Lake, MD
https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8&tab=history&a=13#contacts-locations-card
Um, misiu, regarding your 82% yodeling for years in the 394 patient study--- CD12 critical showing 82% mortality benefit
Why was there no Principal Investigator listed under the Study Details tab and clearly shows No information provided
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
CytoDyn, Inc.
Collaborators
No information provided
Investigators
No information provided
https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8
United States
Alabama Locations
Alexander City, Alabama, United States, 35010
Advanced Cardiovascular, LLC
California Locations
Fullerton, California, United States, 92835
St. Jude Medical Center
Los Angeles, California, United States, 90095
UCLA
Florida Locations
Tampa, Florida, United States, 33612
James A. Haley Veterans' Hospital
Georgia Locations
Gainesville, Georgia, United States, 30501
Center for Advanced Research & Education (CARE)
Massachusetts Locations
Boston, Massachusetts, United States, 02215
Beth Israel Deaconess Medical Center
New Jersey Locations
Livingston, New Jersey, United States, 07052
St. Barnabas
Morristown, New Jersey, United States, 07962-1905
Atlantic Health System Hospital
Teaneck, New Jersey, United States, 07666
Holy Name Medical Center
New York Locations
Bronx, New York, United States, 10467
Montefiore Medical Center
Brooklyn, New York, United States, 11229
New York Community Hospital of Brooklyn
North Carolina Locations
Winston-Salem, North Carolina, United States, 27103
Novant Health
Ohio Locations
Columbus, Ohio, United States, 43215
Ohio Health
Oregon Locations
Corvallis, Oregon, United States, 97330
Good Samaritan Hospital Corvallis
Portland, Oregon, United States, 97239
Oregon Health and Sciences University
Texas Locations
Dallas, Texas, United States, 75204
Baylor Scott & White Research Institute
Houston, Texas, United States, 77030
Baylor College of Medicine
Houston, Texas, United States, 77030
University of Texas
https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8
ClinicalTrials.gov ID NCT04347239
Sponsor CytoDyn, Inc.
Information provided by CytoDyn, Inc. (Responsible Party)
Last Update Posted 2022-01-14
https://www.clinicaltrials.gov/study/NCT04347239?intr=leronlimab&rank=8&tab=table
Yep, misius grubby little fingerprints are all over the article...case in point with the 2nd sentence in the 1st paragraph--- Proven means their drug reduced 14 day mortality by 82% in a phase 3 clinical trial.